| References |
| 1 |
Isoniazid was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
| 2 |
The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog. World J Microbiol Biotechnol. 2019 Oct 31;35(11):174.
|
| 3 |
Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro-drug isoniazid. FEBS Lett. 2015 Jan 2;589(1):131-7.
|
| 4 |
Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
|
| 5 |
Exploration of inhibition potential of isoniazid and its metabolites towards CYP2E1 in human liver microsomes through LC-MS/MS analysis J Pharm Biomed Anal. 2021 Sep 5;203:114223. doi: 10.1016/j.jpba.2021.114223.
|
| 6 |
Molecular mechanism for the activation of the potent hepatotoxin acetylhydrazine: Identification of the initial N-centered radical and the secondary C-centered radical intermediates. Free Radic Biol Med. 2023 Aug 1;204:20-27. doi: 10.1016/j.freeradbiomed.2023.04.010.
|
| 7 |
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS. Molecules. 2022 Dec 6;27(23):8607. doi: 10.3390/molecules27238607.
|
| 8 |
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis. Br J Clin Pharmacol. 2023 Feb;89(2):714-726. doi: 10.1111/bcp.15527.
|
| 9 |
The tuberculosis prodrug isoniazid bound to activating peroxidases
|
